Iovance - IOVA Net earnings per share for the last four quarters

Official company branding of Iovance (IOVA)

Iovance Biotherapeutics brings together top immunologists, offering career growth driven by its first FDA-approved product. The brand's impeccable reputation following the launch of Amtagvi establishes the company as a medical flagship. The 12-month YoY earnings per share growth rate reflects a trend where 56.60 characterizes this valuation parameter. However, colossal infrastructure costs and strict patent controls are hindering development.

Iovance Biotherapeutics, Inc. (IOVA) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

IOVA (Iovance Biotherapeutics, Inc.): analytical breakdowns and indicator data

Initial company analysis:IOVA, Iovance
Mass-produced product of iovance.com

Iovance Biotherapeutics (IOVA) leverages its first-mover status in cancer therapy and the approval of Amtagvi to create high barriers to entry, securing a long-term competitive advantage. By analyzing the rolling year-over-year EPS growth chart, an investor assesses the 12-month net income per share trend, which reveals the actual efficiency of capital and prevents overpaying for the asset when compared to industry peers.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months